Recognizing and preventing antibiotic-associated complications in the critical care setting

Critical Care Nursing Quarterly

Volumn 20, Issue 3, 1997, Pages 1-11

  Foxworth, John ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminoglycosides; Antibiotics; Cephalosporins; Clindamycin; Macrolides; Metronidazole; Toxicity; Trimethop rim sulfamethoxazole; Vancomycin; lactam

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; MACROLIDE; METRONIDAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; VANCOMYCIN; WARFARIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CARDIOTOXICITY; DRUG HYPERSENSITIVITY; GASTROINTESTINAL TOXICITY; HUMAN; INTENSIVE CARE; NEPHROTOXICITY; NEUROTOXICITY; NURSING; OTOTOXICITY; PHLEBITIS; REVIEW; SIDE EFFECT; SKIN TOXICITY;

EID: 0030714661     PISSN: 08879303     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002727-199711000-00002     Document Type: Review

References (35)

1. Kollef MH. Antibiotic use and antibiotic resistance in the intensive care unit: are we curing or creating disease? Heart Lung. 1994;23:363-367.
2. Cunha BA. Intensive care, not intensive antibiotics. Heart Lung. 1994;23:361-362.
3. Anne S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy, Asthma, and Immunol. 1995;74:167-170.
4. Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med. 1987;107:204-215.
5. Ennis DM, Cobbs CG. The newer cephalosporins, aztreonam and imipenem. Infect Dis Clin North Am. 1995;9:687-713.
6. Hansten PD, Horn JR. Drug Interactions and Updates Quarterly. Vancouver, Wash: Applied Therapeutics, Inc., 1997.
7. Parry MF. The penicillins. Med Clin North Am. 1987;71:1093-1112.
8. Sobel JD. Imipenem and aztreonam. Infect Dis Clin North Am. 1989;3:613-624.
9. Chow JW, Fine MJ, Shlaes DM, et. al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991; 115:585-590.
10. Sanders CC. New β-lactams: new problems for the internist. Ann Intern Med. 1991;115:650-651.
11. Levison ME. Pharmacodynamics of antimicrobial agents: bactericidal and postantibiotic effects. Infect Dis Clin North Am. 1995;9:483-495.
12. Pancoast SJ. Aminoglycoside antibiotics in clinical use. Med Clin North Am. 1988;72:581-612.
13. Levison ME. New dosing regimens for aminoglycoside antibiotics. Ann Intern Med. 1992;117:693-694.
14. McCormack JP, Jewesson PJ. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis. 1992;14:320-339.
15. Zarama M, Abraham PA. Drug-induced renal disease. In: Pharmacotherapy. 3rd ed. Stamford, Conn: Appleton & Lange; 1997.
16. Benet LZ, Kroetz DL, Sheine LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 9th ed. New York:McGraw-Hill; 1996.
17. Zaske DE. Aminoglycosides. In: Applied Pharmacokinetics. 3rd ed. Vancouver, Wash: Applied Therapeutics, Inc; 1992.
18. Aweeka FT. Dosing of drugs in renal failure. In: Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver, Wash: Applied Therapeutics, Inc; 1995.
19. Bennett WM, Aronoff GR, Golper TA, Morrison G, Brater DC, Singer I. Drug Prescribing in Renal Failure. 3rd ed. Philadelphia, Pa: American College of Physicians; 1994.
20. Chambers HF, Sande MA. The aminoglycosides. In: Goodman LS, Gilman A, eds. The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996.
21. Lundstrom TS, Sobel JD. Vancomycin, trimethoprimsulfamethoxazole, and rifampin. Infect Dis Clin North Am. 1995;9:747-767.
22. Levine JF. Vancomycin. Med Clin North Am. 1987;71:1135-1145.
23. Matzke GR. Vancomycin. In: Applied Pharmacokinetics. 3rd ed. Vancouver, Wash: Applied Therapeutics, Inc., 1992.
24. Freeman CD, Quintiliani, R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother. 1993;27:594-598.
25. Hendershot EF. Fluoroquinolones. Infect Dis Clin North Am. 1995;9:715-730.
26. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.
27. Brittain DC. Erythromycin. Med Clin North Am. 1987;71:1147-1154.
28. Oberg KC, Bauman JL. QT prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy. 1995;15:687-692.
29. Roujeau JC, Stem RS. Severe adverse reactions to drugs. N Engl J Med. 1994;331:1272-1285.
30. Masur H, Kovacs JA. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Infect Dis Clin North Am. 1988;2:419-428.
31. Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med. 1993;119:291-295.
32. Velazquez H, Perazella MA, Wright FS, Ellison DH. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296-301.
33. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med. 1994;121:676-683.
34. Scully BE. Metronidazole. Med Clin North Am. 1988;72:613-621.
35. Johnson DH, Cunha BA. Drug fever. Infect Dis Clin North Am. 1996;10:85-91.